Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Am J Vet Res ; 66(1): 100-7, 2005 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-15691043

RESUMO

OBJECTIVES: To determine the effects of oral administration of tilmicosin in piglets experimentally infected with Actinobacillus pleuropneumoniae. ANIMALS: Forty 3-week-old specific-pathogen free piglets. PROCEDURES: Piglets were assigned to 1 of 4 groups as follows: 1) uninfected sham-treated control piglets; 2) infected untreated piglets that were intratracheally inoculated with 10(7) CFUs of A pleuropneumoniae; 3) infected treated piglets that were intratracheally inoculated with A pleuropneumoniae and received tilmicosin in feed (400 ppm [microg/g]) for 7 days prior to inoculation; or 4) infected treated piglets that were intratracheally inoculated with A pleuropneumoniae and received chlortetracycline (CTC) in feed (1100 ppm [microg/gl) for 7 days prior to inoculation. Bronchoalveolar lavage (BAL) fluid and lung tissue specimens of piglets for each group were evaluated at 3 or 24 hours after inoculation. For each time point, 4 to 6 piglets/group were studied. RESULTS: Feeding of CTC and tilmicosin decreased bacterial load in lungs of infected piglets. Tilmicosin delivered in feed, but not CTC, enhanced apoptosis in porcine BAL fluid leukocytes. This was associated with a decrease in LTB4 concentrations in BAL fluid of tilmicosin-treated piglets, compared with untreated and CTC-treated piglets, and also with a significant decrease in the number of pulmonary lesions. Tilmicosin inhibited infection-induced increases in rectal temperatures, as measured in untreated and CTC-treated piglets. Pulmonary neutrophil infiltration and prostaglandin E2 concentrations in the BAL fluid were not significantly different among groups at any time. CONCLUSIONS AND CLINICAL RELEVANCE: Oral administration of tilmicosin to infected piglets induces apoptosis in BAL fluid leukocytes and decreases BAL fluid LTB4 concentrations and inflammatory lung lesions.


Assuntos
Infecções por Actinobacillus/veterinária , Actinobacillus pleuropneumoniae , Anti-Inflamatórios não Esteroides/uso terapêutico , Macrolídeos/uso terapêutico , Pneumonia Bacteriana/veterinária , Doenças dos Suínos/tratamento farmacológico , Tilosina/análogos & derivados , Tilosina/uso terapêutico , Infecções por Actinobacillus/tratamento farmacológico , Infecções por Actinobacillus/fisiopatologia , Ração Animal , Animais , Apoptose/efeitos dos fármacos , Dinoprostona/biossíntese , Leucócitos/efeitos dos fármacos , Leucotrieno B4/biossíntese , Peroxidase/biossíntese , Fagocitose/efeitos dos fármacos , Pneumonia Bacteriana/tratamento farmacológico , Suínos , Doenças dos Suínos/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA